Ramsey Lake Pharma preclinical data

In non-resistant MM cell lines, VR23 plus Velcade bortezomib reduced cancer cell growth to 1.6% vs. 12.5% for Velcade alone. In Velcade-resistant MM cell lines, VR23 plus Velcade reduced cancer cell ...